Nanoporous capsules of block co-polymers of [(MeO-PEG-NH)-b-(L-GluA)]-PCL for the controlled release of anticancer drugs for therapeutic applications

Herein, new nanoporous capsules of the block co-polymers of MeO-PEG-NH-(L-GluA)10 and polycaprolactone (PCL) have been synthesized through a surfactant-free cost-effective self-assembled soft-templating approach for the controlled release of drugs and for therapeutic applications. The nanoporous pol...

Full description

Saved in:
Bibliographic Details
Published in:Nanotechnology 2016-03, Vol.27 (12), p.125101-125112
Main Authors: Amgoth, Chander, Dharmapuri, Gangappa, Kalle, Arunasree M, Paik, Pradip
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Blocking
Cancer
cancer therapy
Capsules - chemistry
Cell Survival - drug effects
Cellular
Controlled release
Copolymers
Delayed-Action Preparations
DOX
Doxorubicin - pharmacology
Drugs
Enrichment
Glucose Transporter Type 1
HEK293 Cells
Humans
Imatinib Mesylate - pharmacology
ITM
K562 Cells
nanomedicine
Nanopores
Nanostructure
Neoplasms - drug therapy
Particle Size
Polyesters - chemistry
polymer capsules
Polymers - chemical synthesis
Polymers - chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Herein, new nanoporous capsules of the block co-polymers of MeO-PEG-NH-(L-GluA)10 and polycaprolactone (PCL) have been synthesized through a surfactant-free cost-effective self-assembled soft-templating approach for the controlled release of drugs and for therapeutic applications. The nanoporous polymer capsules are designed to be biocompatible and are capable of encapsulating anticancer drugs (e.g., doxorubicin hydrochloride (DOX) and imatinib mesylate (ITM)) with a high extent (∼279 and ∼480 ng g−1, respectively). We have developed a nanoformulation of porous MeO-PEG-NH-(L-GluA)10-PCL capsules with DOX and ITM. The porous polymer nanoformulations have been programmed in terms of the release of anticancer drugs with a desired dose to treat the leukemia (K562) and human carcinoma cells (HepG2) in vitro and show promising IC50 values with a very high mortality of cancer cells (up to ∼96.6%). Our nanoformulation arrests the cell divisions due to 'cellular scenescence' and kills the cancer cells specifically. The present findings could enrich the effectiveness of idiosyncratic nanoporous polymer capsules for use in various other nanomedicinal and biomedical applications, such as for killing cancer cells, immune therapy, and gene delivery.
ISSN:0957-4484
1361-6528
DOI:10.1088/0957-4484/27/12/125101